Mineral Investor Chen Lin Argues Silver Moving From Bullion to Physical Asset, Reveals Picks
Source: Streetwise Reports  (12/16/25)
Seasoned minerals investor Chen Lin argues silver's 50-year breakout is not a routine cycle but a transition from bullion to a tightening "critical minerals" market. Read on to see what some of his top picks are, including one biotech company he thinks could be the next Eli Lilly. More >

Market Experts Uncover Excellent Buys During December 'Silly Season' Tax Selloff
Source: Streetwise Reports  (12/15/25)
Every December, tax-loss selling tends to exert downward pressure on certain stocks as investors aim to offset capital gains. Streetwise Reports asked some of its frequent contributors to add their own thoughts on the other "holiday season" and give their own picks for good bargains. More >

Tech Firm Partners to Advance AI-Powered Support for MDs
Source: Streetwise Reports  (12/11/25)
Rocket Doctor AI Inc.'s (AIDR:CSE; TREIF:OTC; 939:FRA) Clinical Decision Support System is being deployed in Alberta, Canada, on a small scale for a trial period with the goal of expanding it province-wide next year. This company's stock is rated Speculative Buy; read on to learn why. More >

Clean Tech Co.'s 'Forever Chemicals' Solution Featured in Industry Magazine
Source: Streetwise Reports  (12/8/25)
BioLargo Inc. (BLGO:OTCQX) subsidiary BioLargo Equipment Solutions & Technologies Inc. (BEST) is prominently featured in Chemical Engineering magazine for its advancements in electrostatic PFAS treatment technology. Find out why one expert likes this stock long-term. More >

AI-Powered Healthcare Co. Gains Traction as US Expansion Accelerates
Source: John Newell  (12/8/25)
John Newell of John Newell & Associates shares why he thinks Rocket Doctor AI (AIDR:CSE; TREIF:OTC; 939:FRA) is a Speculative Buy. More >

Data on 2 Drugs, Identified Via AI, Shared at Conference
Source: Dr. Douglas Loe  (12/4/25)
Rakovina Therapeutics Inc.'s (RKV:TSX.V) preclinical ATR inhibitors, Compound A and Compound C, exhibit similarities to two clinical-stage drugs in the same class, noted a Leede Financial Inc. report. More >

AI Breakthroughs Drive New Momentum in Oncology Research
Source: Streetwise Reports  (12/3/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) reported financial and operational results for Q3, detailing continued progress across its AI-enabled DNA Damage Response programs. The company highlighted new scientific data, expanded collaborations, and increased visibility at major oncology conferences. More >

Water Treatment Firm Finds High-Performance Solution for $2.99B PFAS Market
Source: Streetwise Reports  (12/3/25)
Chemical Engineering magazine features BioLargo Inc. (OTCQX:BLGO) subsidiary BioLargo Equipment Solutions & Technologies Inc. (BEST) for its advancements in electrostatic PFAS treatment technology. Read why one expert likes this stock long-term. More >

Analyst: Scientific Instrument Co.'s Q3/25 Results 'Soft'
Source: Dr. Douglas Loe  (12/2/25)
Nanalysis Scientific Corp. (NSCI:TSX.V; NSCIF:OTC; 1N1:FSE) has its price target lowered as a result, but is expected to improve its financials in the near term, noted a Leede Financial Inc. report. More >

Biotech Co. Advances Precision Psychiatry Breakthrough Pipeline While Analysts' Sentiment Remains Positive
Source: Streetwise Reports  (12/1/25)
Alto Neuroscience Inc. (ANRO:NYSE) continues moving its clinical programs forward, receives regulatory clarity and raises US$50 million, during the past four months. Read on for analysts' thoughts on this biopharma. More >

Biotech Co.'s Q3/25 Progress on Lead Programs Steady
Source: Patrick Trucchio  (12/1/25)
Alto Neuroscience Inc.'s (ANRO:NYSE) clinical execution and regulatory momentum advance the firm's biomarker-guided precision psychiatry pipeline, noted an H.C. Wainwright & Co. report. More >

AI Identifies Preclinical Cancer Compounds With Potential to Reach the Brain
Source: Streetwise Reports  (11/26/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) presented new data at the 2025 Society for Neuro-Oncology Annual Meeting on its PARP1-selective inhibitors, with central nervous system penetration. The findings demonstrated how Rakovina's AI-powered discovery platform identified promising drug candidates designed to target brain-involved cancers. More >

Clean Tech Co.: Wound Care Subsidiary Set to Take Off; 3Q Results
Source: Streetwise Reports  (11/19/25)
Clean technology innovation company BioLargo Inc. releases its financial and operational results for the three- and nine-month periods ending September 30. It also has announced an agreement to distribute its cutting-edge wound irrigation solution nationally. More >

US$12 Billion RNA Deal Triggers Sector Shakeup
Source: Streetwise Reports  (11/14/25)
Avidity Biosciences Inc. (RNA:NASDAQ) reported Q3 results alongside news of its US$12 billion acquisition by Novartis. The deal comes as three RNA drugs approach major regulatory filings through 2026. More >

Preclinical Compounds Perform Better Than Existing Drugs
Source: Dr. Douglas Loe  (11/13/25)
Rakovina Therapeutics Inc.'s (RKV:TSX.V) AI-designed Compounds A, B and C demonstrated the same ATR blocking activity as three of Big Pharma's existing, clinical-stage drugs but at much lower concentrations, noted a Leede Financial Inc. report. More >

Lead Drug Faces Uncertain FDA Path After Phase 3 Miss
Source: Streetwise Reports  (11/13/25)
aTyr Pharma Inc. (ATYR:NASDAQ) is seeking regulatory clarity following mixed Phase 3 results for its lead candidate efzofitimod in pulmonary sarcoidosis. The company expects feedback from the FDA in the first quarter of 2026 to help determine a potential path forward. More >

Breakthrough Pill Cuts Bad Cholesterol by Nearly 60% in Major Trials
Source: Streetwise Reports  (11/12/25)
Merck & Co. Inc. (MRK:NYSE) announced that its investigational oral PCSK9 inhibitor, enlicitide, achieved significant LDL-C reductions in two pivotal Phase 3 studies presented at the American Heart Association Scientific Sessions. The once-daily pill demonstrated efficacy comparable to injectable therapies, marking a major step forward in cholesterol management. More >

Clean Tech Finds Massive Energy Savings in PFAS Treatment
Source: Streetwise Reports  (11/5/25)
BioLargo Inc. (BLGO:OTCQX) announces a significant upgrade to its patented Aqueous Electrostatic Concentrator (AEC) system, reducing energy consumption by over 90% in large-scale "forever chemical" treatment for drinking water. More >

Biotech to Fast Track Phase 3 Depression Trial
Source: Dr. Myles Minter  (10/30/25)
Alto Neuroscience Inc. (ANRO:NYSE) intends to carry out this newly added study, supported by a recent financing, and the previously planned Phase 2b trial simultaneously, noted a William Blair report. More >

2 Key Catalysts Ahead for Developer of Psych Drugs
Source: Patrick Trucchio  (10/28/25)
Alto Neuroscience Inc. (ANRO:NYSE) expects to release topline trial data in 2025 and commence a separate study in 2026, noted an H.C. Wainwright & Co. report. More >

Co. Speeds Up Development of New Drug for Depression
Source: Andrew Tsai  (10/28/25)
Alto Neuroscience Inc. (ANRO:NYSE) plans Phases 2b and 3 trials of its asset, ALTO-207, in treatment-resistant depression, noted a Jefferies report. More >

Price Target on Psychiatric Drug Biotech Boosted 200%
Source: Dr. Laura Chico  (10/27/25)
Alto Neuroscience Inc. (ANRO:NYSE) completed a US$50 million equity raise and announced plans to accelerate development of its recently acquired asset in treatment-resistant depression, noted a Wedbush report. More >

US Biopharma In-Licenses 3 New Assets
Source: Dr. Martin Fan  (10/24/25)
Zenas BioPharma Inc.'s (ZBIO:NASDAQ) target price is increased 14% to reflect the Phase 3 investigative multiple sclerosis drug included in this recent deal, noted a Wedbush report. More >

Chen's High-Grade Gold, Silver Plays for Q4
Source: Streetwise Reports  (10/23/25)
It has been quite a year for precious metals such as gold and silver, and Chen Lin's top stock picks for the quarter bear that out. Which companies have the most upside? More >

AI Cancer Discovery Shows Breakthrough in Brain-Targeting Treatment
Source: Streetwise Reports  (10/20/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) is set to unveil new preclinical data from its AI-driven ATR inhibitor program at a major international cancer conference in Boston. The findings highlight strong efficacy and blood-brain barrier permeability, a potential breakthrough for hard-to-treat tumors and brain metastases. More >